分泌粒蛋白Ⅲ抗体治疗眼底新生血管的研究进展  

Research progress on soluble anti-Secretogranin Ⅲ in fundus neovascularization

作　　者：杨彬彬 靳荷 丁芝祥[2] Bin-Bin Yang;He Jin;Zhi-Xiang Ding(Guilin Medical College,Guilin 541000,Guangxi Zhuang Autonomous Region,China;Department of Ophthalmology,Affiliated Hospital of Guilin Medical College,Guilin 541000,Guangxi Zhuang Autonomous Region,China)

机构地区：[1]桂林医学院,中国广西壮族自治区桂林市541000 [2]桂林医学院附属医院眼科,中国广西壮族自治区桂林市541000

出　　处：《国际眼科杂志》2020年第5期827-830,共4页International Eye Science

基　　金：广西自然科学基金项目(No.2018GXNSFBA050055)。

摘　　要：分泌粒蛋白Ⅲ(SecretograninⅢ,Scg3/SgⅢ)是一个新近发现的血管生长因子,相关体内、体外研究已证实Scg3在眼底新生血管的形成中具有重要作用。近年来,将Scg3抗体应用于眼底新生血管的治疗也取得了一些进展,其作用机制与血管内皮生长因子(vascular endothelial growth factor,VEGF)不同,Scg3仅在病理性新生血管中表达,在正常血管中不表达,是一种新发现的具有高选择性表达的血管生长因子。本文从Scg3分子结构、信号传导通路以及其在眼底视网膜及脉络膜新生血管治疗中的最新进展进行了综述,旨在为视网膜及脉络膜新生血管的治疗提供一个新的治疗思路。·Scretogranin III(Scretogranin III,Scg3/SgIII)is a newly discovered angiogenic factor.Related studies in vivo and in vitro have confirmed that Scg3 plays an important role in the formation of fundus neovascularization.In recent years,some progress has been made in the treatment of fundus neovascularization with Scg3 antibody.It’s mechanism of action is different from Vascular endothelial growth factor(VEGF).Scg3 is only expressed in pathological neovascularization,but in normal blood vessels,never be expressed,it is a newly discovered angiogenic factor with high selectivity.This paper summarizes the latest progress about its molecular structure of Scg3,signal transduction pathways and their applications in retinal neovascularization,the aim is to provide a new treatment idea for retinal neovascularization and choroidal neovascularization.

关 键 词：分泌粒蛋白Ⅲ 血管内皮生成因子 视网膜新生血管 脉络膜新生血管 

分 类 号：R73[医药卫生—肿瘤]